期刊文献+

Zevalin和Bexxar在放射免疫治疗中的研究进展 被引量:2

Current research of Zevalin and Bexxar in the field of radioimmunotherapy
下载PDF
导出
摘要 应用核素偶联的单抗进行放射免疫治疗已经被公认为新一代治疗难治非霍奇金淋巴瘤(non-Hodgkin’slymphoma,NHL)的有效手段。90Y-ibritumomab tiuxetan(Zevalin)和131I-tositumomab tiuxetan(Bexxar)等CD20核素标记的单克隆抗体在难治或复发的滤泡型/低度恶性或转化型非霍奇金淋巴瘤的治疗研究中取得显著成效。本文将对Zevalin和Bexxar的作用机制、治疗方法、临床研究及安全性作一个回顾性的总结及展望。 Radioimmunotherapy using monoclonal antibodies incorporated with radionuclide has been showed to be an effective agent for refractory non-Hodgkin's lymphoma (NHL). Many anti-CD20 antibodies labeled with radionucIide, such as ^90 Y-ibritumomab tiuxetan (Zevalin) and ^131 I-tositumomab tiuxetan (Bexxar), have been reported to be effective for the treatment of patients with relapsed or refractory low-grade, follicular, or transformed NHL. This review summarizes the current advance in clinical trials and studies of Zevalin and Bexxar for the treatment of NHL patients.
作者 刘钊 李军民
出处 《复旦学报(医学版)》 CAS CSCD 北大核心 2009年第6期786-788,共3页 Fudan University Journal of Medical Sciences
关键词 非霍奇金淋巴瘤 放射免疫治疗 放射同位素 CD20 non-Hodgkin's lymphoma radioimmunotherapy radioisotope CD20
  • 相关文献

参考文献20

二级参考文献52

共引文献19

同被引文献22

  • 1Dworzak M N,Schumich A,Printz D,et al.CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment:setting the stage for anti-CD20 directed immunotherapy[J].Blood,2008,112(10):3982-3988.
  • 2Zhou X,Hu W,Qin X.The role of complement in the mechanism of action of rituximab for B-cell lymphoma:implications for therapy[J].Oncologist,2008,13(9):954-966.
  • 3van Meerten T,Hagenbeek A.CD20-targeted therapy:a breakthrough in the treatment of non-Hodgkin's lymphoma[J].Neth J Med,2009,67(7):251-259.
  • 4Sieber S,Gdynia G,Roth W,et al.Combination treatment of malignant B cells using the anti-CD20 antibody rituximab and the anti-malarial artesunate[J].Int J Oncol,2009,35(1):149-158.
  • 5Tilly H,Zelenetz A.Treatment of follicular lymphoma:current status[J].Leuk Lymphoma,2008,49(Suppl 1):7-17.
  • 6Colombat P,Brousse N,Morschhauser F,et al.Single treatment with rituximab monotherapy for low-tumor burden follicular lymphoma (FL):survival analyses with extended follow-up of 7 years[A].ASH Annual Meeting Abstracts,2006,108:486.
  • 7Ghielmini M,Schmitz SF,Cogliatti SB,et al.Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule[J].Blood,2004,103:4416-4423.
  • 8Salles G,Mounier N,de Guibert S,et al.Rituximab combined with chemotherapy and interferon in follicular lymphoma patients:results of the GELA-GOELAMS FL2000 study[J].Blood,2008,112(13):4824-4831.
  • 9Czuczman MS,Weaver R,Alkuzweny B,et al.Prolonged clinic and molecular remission in patients with low-grade or follicular non Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy 9-year follow-up[J].J Clin Oncol,2004,22:4711-4716.
  • 10Sonoki T,Li Y,Miyanishi S,et al.Establishment of a novel CD20 negative mature B-cell line,WILL2,from a CD20 positive diffuse large B-cell lymphoma patient treated with rituximab[J].Int J Hematol,2009,89(3):400-402.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部